FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions is based on using as a part of compositions, combinations and devices related to a phenotype involving a decrease of body fat and plasma triglycerides, and an increase of saturation of two or more chemically synthesised or chemically modified polynucleotides, which are specifically hybridised with two or more polynucleotide targets, which are differentially expressed in animals showing the phenotype involving the decrease of body fat and plasma triglycerides and the increase of saturation as a result of the continuous regular administration of a substance which has an effect on one or more parameters of nutrient absorption, saturation, lipid metabolism and fat recovery, wherein the polynucleotide targets contain a gene specified in genes coding FAS proteins, vistafin and GPR119.
EFFECT: group of inventions enables identifying the new compounds having the effect on one or more of these parameters and modulating the related animal's phenotype.
17 cl, 2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
CARDIAC AGING BIOMARKER AND METHODS FOR USING THEM | 2010 |
|
RU2562174C2 |
PROFILES OF EXPRESSION OF GENES ASSOCIATED WITH LEAN PHENOTYPE | 2009 |
|
RU2532837C2 |
RAD3 POLYPEPTIDE ATR HOMOLOGUES, POLYNUCLEUTIDES AND RELATED METHODS AND MATERIALS | 1996 |
|
RU2252256C2 |
COMPOSITIONS AND METHODS FOR TREATMENT OF OSTEOARTHRITIS | 2009 |
|
RU2619553C2 |
CLOSTRIDIAL TOXIN NetB | 2008 |
|
RU2474587C2 |
COMPOSITIONS AND METHODS FOR DIAGNOSING AND MONITORING HYPERTHYROIDISM IN FELINES | 2012 |
|
RU2593952C2 |
SEEDS OF TRANSGENIC PLANTS WITH HIGH CONTENT OF LYSINE | 2006 |
|
RU2460281C2 |
TISSUE-SPECIFIC BIOMARKERS OF AGEING | 2010 |
|
RU2557313C2 |
MODIFIED DENDRITIC CELLS AND THEIR APPLICATION FOR MALIGNANT TUMOURS TREATMENT | 2013 |
|
RU2644210C2 |
MODIFIED DENDRITE CELLS AND THEIR USE IN TREATMENT OF MALIGNANT TUMOURS | 2008 |
|
RU2484132C2 |
Authors
Dates
2015-04-10—Published
2009-08-10—Filed